Comments
Lupin Ltd, India's third-largest drugmaker, has reported a 48 per cent rise in quarterly net profit, outpacing analysts’ estimates mainly due to higher drug sales in its largest market, the United States.
Net profit for the January-March quarter was Rs 807 crore ($119.91 million), compared with Rs 547 crore a year earlier. Analysts polled by Thomson Reuters expected an average profit of Rs 678 crore.
Lupin has benefitted in recent months from a steady pace of new drug approvals in the United States at a time when most of its peers have been facing delays in getting approvals due to regulatory troubles.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.